![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: MMP2 |
Gene summary for MMP2 |
![]() |
Gene information | Species | Human | Gene symbol | MMP2 | Gene ID | 4313 |
Gene name | matrix metallopeptidase 2 | |
Gene Alias | CLG4 | |
Cytomap | 16q12.2 | |
Gene Type | protein-coding | GO ID | GO:0000003 | UniProtAcc | P08253 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
4313 | MMP2 | AEH-subject1 | Human | Endometrium | AEH | 5.07e-19 | -6.37e-01 | -0.3059 |
4313 | MMP2 | AEH-subject2 | Human | Endometrium | AEH | 1.85e-24 | -7.09e-01 | -0.2525 |
4313 | MMP2 | AEH-subject3 | Human | Endometrium | AEH | 9.84e-33 | -7.89e-01 | -0.2576 |
4313 | MMP2 | AEH-subject4 | Human | Endometrium | AEH | 2.50e-13 | -6.27e-01 | -0.2657 |
4313 | MMP2 | AEH-subject5 | Human | Endometrium | AEH | 2.36e-40 | -8.18e-01 | -0.2953 |
4313 | MMP2 | EEC-subject1 | Human | Endometrium | EEC | 1.99e-26 | -7.44e-01 | -0.2682 |
4313 | MMP2 | EEC-subject2 | Human | Endometrium | EEC | 1.20e-41 | -8.14e-01 | -0.2607 |
4313 | MMP2 | EEC-subject3 | Human | Endometrium | EEC | 3.14e-31 | -6.47e-01 | -0.2525 |
4313 | MMP2 | EEC-subject4 | Human | Endometrium | EEC | 7.49e-29 | -7.61e-01 | -0.2571 |
4313 | MMP2 | EEC-subject5 | Human | Endometrium | EEC | 6.74e-33 | -7.70e-01 | -0.249 |
4313 | MMP2 | GSM5276935 | Human | Endometrium | EEC | 3.89e-30 | -7.50e-01 | -0.123 |
4313 | MMP2 | GSM6177620_NYU_UCEC1_lib1_lib1 | Human | Endometrium | EEC | 1.79e-24 | -7.22e-01 | -0.1869 |
4313 | MMP2 | GSM6177620_NYU_UCEC1_lib2_lib2 | Human | Endometrium | EEC | 1.49e-24 | -6.90e-01 | -0.1875 |
4313 | MMP2 | GSM6177620_NYU_UCEC1_lib3_lib3 | Human | Endometrium | EEC | 1.99e-28 | -6.57e-01 | -0.1883 |
4313 | MMP2 | GSM6177621_NYU_UCEC2_lib1_lib1 | Human | Endometrium | EEC | 1.71e-39 | -7.78e-01 | -0.1934 |
4313 | MMP2 | GSM6177622_NYU_UCEC3_lib1_lib1 | Human | Endometrium | EEC | 1.19e-42 | -8.16e-01 | -0.1917 |
4313 | MMP2 | GSM6177622_NYU_UCEC3_lib2_lib2 | Human | Endometrium | EEC | 6.57e-48 | -8.29e-01 | -0.1916 |
4313 | MMP2 | P2T-E | Human | Esophagus | ESCC | 1.02e-09 | 3.20e-01 | 0.1177 |
4313 | MMP2 | P4T-E | Human | Esophagus | ESCC | 1.56e-04 | 1.39e+00 | 0.1323 |
4313 | MMP2 | P9T-E | Human | Esophagus | ESCC | 1.22e-07 | 1.70e+00 | 0.1131 |
Page: 1 2 3 4 5 |
![]() |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | ![]() |
Colorectum | SER | ![]() |
Colorectum | MSS | ![]() |
Colorectum | MSI-H | ![]() |
Colorectum | FAP | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:00229049 | Cervix | CC | respiratory electron transport chain | 42/2311 | 114/18723 | 1.67e-11 | 4.77e-09 | 42 |
GO:00453339 | Cervix | CC | cellular respiration | 66/2311 | 230/18723 | 2.07e-11 | 5.39e-09 | 66 |
GO:00725949 | Cervix | CC | establishment of protein localization to organelle | 99/2311 | 422/18723 | 1.23e-10 | 2.11e-08 | 99 |
GO:00229009 | Cervix | CC | electron transport chain | 53/2311 | 175/18723 | 2.23e-10 | 3.43e-08 | 53 |
GO:00060919 | Cervix | CC | generation of precursor metabolites and energy | 105/2311 | 490/18723 | 7.40e-09 | 6.61e-07 | 105 |
GO:00026837 | Cervix | CC | negative regulation of immune system process | 94/2311 | 434/18723 | 2.63e-08 | 1.87e-06 | 94 |
GO:00603267 | Cervix | CC | cell chemotaxis | 73/2311 | 310/18723 | 2.82e-08 | 1.96e-06 | 73 |
GO:00159809 | Cervix | CC | energy derivation by oxidation of organic compounds | 74/2311 | 318/18723 | 3.83e-08 | 2.53e-06 | 74 |
GO:00975298 | Cervix | CC | myeloid leukocyte migration | 56/2311 | 220/18723 | 7.21e-08 | 4.15e-06 | 56 |
GO:00305957 | Cervix | CC | leukocyte chemotaxis | 57/2311 | 230/18723 | 1.48e-07 | 7.07e-06 | 57 |
GO:00068399 | Cervix | CC | mitochondrial transport | 60/2311 | 254/18723 | 4.21e-07 | 1.67e-05 | 60 |
GO:00509007 | Cervix | CC | leukocyte migration | 78/2311 | 369/18723 | 1.09e-06 | 3.80e-05 | 78 |
GO:00614588 | Cervix | CC | reproductive system development | 87/2311 | 427/18723 | 1.37e-06 | 4.55e-05 | 87 |
GO:00486088 | Cervix | CC | reproductive structure development | 86/2311 | 424/18723 | 1.90e-06 | 5.97e-05 | 86 |
GO:000660510 | Cervix | CC | protein targeting | 68/2311 | 314/18723 | 2.17e-06 | 6.55e-05 | 68 |
GO:00026857 | Cervix | CC | regulation of leukocyte migration | 50/2311 | 210/18723 | 2.95e-06 | 8.31e-05 | 50 |
GO:00026888 | Cervix | CC | regulation of leukocyte chemotaxis | 34/2311 | 122/18723 | 3.00e-06 | 8.38e-05 | 34 |
GO:00509203 | Cervix | CC | regulation of chemotaxis | 51/2311 | 223/18723 | 8.03e-06 | 1.86e-04 | 51 |
GO:00705859 | Cervix | CC | protein localization to mitochondrion | 33/2311 | 125/18723 | 1.46e-05 | 2.90e-04 | 33 |
GO:00512713 | Cervix | CC | negative regulation of cellular component movement | 73/2311 | 367/18723 | 2.22e-05 | 3.95e-04 | 73 |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
hsa0541525 | Endometrium | AEH | Diabetic cardiomyopathy | 86/1197 | 203/8465 | 2.62e-23 | 1.22e-21 | 8.90e-22 | 86 |
hsa0541826 | Endometrium | AEH | Fluid shear stress and atherosclerosis | 43/1197 | 139/8465 | 2.47e-07 | 3.49e-06 | 2.55e-06 | 43 |
hsa0467026 | Endometrium | AEH | Leukocyte transendothelial migration | 37/1197 | 114/8465 | 4.51e-07 | 6.11e-06 | 4.47e-06 | 37 |
hsa0520518 | Endometrium | AEH | Proteoglycans in cancer | 53/1197 | 205/8465 | 5.43e-06 | 6.53e-05 | 4.78e-05 | 53 |
hsa049337 | Endometrium | AEH | AGE-RAGE signaling pathway in diabetic complications | 28/1197 | 100/8465 | 2.11e-04 | 1.80e-03 | 1.32e-03 | 28 |
hsa0491525 | Endometrium | AEH | Estrogen signaling pathway | 35/1197 | 138/8465 | 3.10e-04 | 2.40e-03 | 1.75e-03 | 35 |
hsa05415111 | Endometrium | AEH | Diabetic cardiomyopathy | 86/1197 | 203/8465 | 2.62e-23 | 1.22e-21 | 8.90e-22 | 86 |
hsa05418112 | Endometrium | AEH | Fluid shear stress and atherosclerosis | 43/1197 | 139/8465 | 2.47e-07 | 3.49e-06 | 2.55e-06 | 43 |
hsa04670111 | Endometrium | AEH | Leukocyte transendothelial migration | 37/1197 | 114/8465 | 4.51e-07 | 6.11e-06 | 4.47e-06 | 37 |
hsa0520519 | Endometrium | AEH | Proteoglycans in cancer | 53/1197 | 205/8465 | 5.43e-06 | 6.53e-05 | 4.78e-05 | 53 |
hsa0493314 | Endometrium | AEH | AGE-RAGE signaling pathway in diabetic complications | 28/1197 | 100/8465 | 2.11e-04 | 1.80e-03 | 1.32e-03 | 28 |
hsa04915111 | Endometrium | AEH | Estrogen signaling pathway | 35/1197 | 138/8465 | 3.10e-04 | 2.40e-03 | 1.75e-03 | 35 |
hsa0541526 | Endometrium | EEC | Diabetic cardiomyopathy | 86/1237 | 203/8465 | 2.59e-22 | 9.46e-21 | 7.05e-21 | 86 |
hsa0541827 | Endometrium | EEC | Fluid shear stress and atherosclerosis | 45/1237 | 139/8465 | 7.76e-08 | 1.22e-06 | 9.07e-07 | 45 |
hsa0467027 | Endometrium | EEC | Leukocyte transendothelial migration | 36/1237 | 114/8465 | 2.97e-06 | 3.91e-05 | 2.91e-05 | 36 |
hsa0520524 | Endometrium | EEC | Proteoglycans in cancer | 52/1237 | 205/8465 | 3.01e-05 | 3.19e-04 | 2.38e-04 | 52 |
hsa0493321 | Endometrium | EEC | AGE-RAGE signaling pathway in diabetic complications | 28/1237 | 100/8465 | 3.68e-04 | 3.03e-03 | 2.26e-03 | 28 |
hsa0491526 | Endometrium | EEC | Estrogen signaling pathway | 34/1237 | 138/8465 | 1.19e-03 | 8.02e-03 | 5.98e-03 | 34 |
hsa0541535 | Endometrium | EEC | Diabetic cardiomyopathy | 86/1237 | 203/8465 | 2.59e-22 | 9.46e-21 | 7.05e-21 | 86 |
hsa0541836 | Endometrium | EEC | Fluid shear stress and atherosclerosis | 45/1237 | 139/8465 | 7.76e-08 | 1.22e-06 | 9.07e-07 | 45 |
Page: 1 2 3 4 5 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
MMP2 | SNV | Missense_Mutation | rs745732650 | c.755N>A | p.Arg252His | p.R252H | P08253 | protein_coding | deleterious(0.01) | probably_damaging(0.998) | TCGA-DF-A2KU-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | Unknown | I/II | Unknown | Unknown | SD |
MMP2 | SNV | Missense_Mutation | c.436C>T | p.Arg146Cys | p.R146C | P08253 | protein_coding | deleterious(0) | probably_damaging(0.98) | TCGA-EO-A22R-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
MMP2 | SNV | Missense_Mutation | novel | c.428C>T | p.Ala143Val | p.A143V | P08253 | protein_coding | tolerated(0.11) | possibly_damaging(0.903) | TCGA-EO-A22T-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
MMP2 | SNV | Missense_Mutation | novel | c.1602N>A | p.Phe534Leu | p.F534L | P08253 | protein_coding | deleterious(0) | probably_damaging(0.993) | TCGA-EY-A1GI-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
MMP2 | SNV | Missense_Mutation | rs746613090 | c.437N>A | p.Arg146His | p.R146H | P08253 | protein_coding | deleterious(0) | probably_damaging(0.956) | TCGA-FI-A2F4-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
MMP2 | SNV | Missense_Mutation | novel | c.657N>C | p.Gln219His | p.Q219H | P08253 | protein_coding | tolerated(0.12) | probably_damaging(0.992) | TCGA-FI-A2F4-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
MMP2 | SNV | Missense_Mutation | c.85G>A | p.Ala29Thr | p.A29T | P08253 | protein_coding | tolerated(0.06) | benign(0.006) | TCGA-FV-A4ZP-01 | Liver | liver hepatocellular carcinoma | Male | >=65 | III/IV | Unknown | Unknown | SD | |
MMP2 | SNV | Missense_Mutation | novel | c.876G>T | p.Lys292Asn | p.K292N | P08253 | protein_coding | tolerated(0.19) | probably_damaging(0.981) | TCGA-ZS-A9CE-01 | Liver | liver hepatocellular carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD |
MMP2 | SNV | Missense_Mutation | novel | c.556N>C | p.Gly186Arg | p.G186R | P08253 | protein_coding | deleterious(0.01) | probably_damaging(0.996) | TCGA-05-4390-01 | Lung | lung adenocarcinoma | Female | <65 | I/II | Chemotherapy | cisplatin | PD |
MMP2 | SNV | Missense_Mutation | rs757888862 | c.1785N>T | p.Lys595Asn | p.K595N | P08253 | protein_coding | tolerated(0.1) | possibly_damaging(0.577) | TCGA-05-4398-01 | Lung | lung adenocarcinoma | Female | <65 | III/IV | Chemotherapy | carboplatin | CR |
Page: 1 2 3 4 5 6 7 8 9 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
4313 | MMP2 | NEUTRAL ZINC METALLOPEPTIDASE, ENZYME, DRUGGABLE GENOME, PROTEASE | inhibitor | 178101832 | ||
4313 | MMP2 | NEUTRAL ZINC METALLOPEPTIDASE, ENZYME, DRUGGABLE GENOME, PROTEASE | SERMS | 15576828 | ||
4313 | MMP2 | NEUTRAL ZINC METALLOPEPTIDASE, ENZYME, DRUGGABLE GENOME, PROTEASE | MARIMASTAT | MARIMASTAT | ||
4313 | MMP2 | NEUTRAL ZINC METALLOPEPTIDASE, ENZYME, DRUGGABLE GENOME, PROTEASE | PMID29130358-Compound-SB-3CT | |||
4313 | MMP2 | NEUTRAL ZINC METALLOPEPTIDASE, ENZYME, DRUGGABLE GENOME, PROTEASE | BMS-275291 | REBIMASTAT | 15041713 | |
4313 | MMP2 | NEUTRAL ZINC METALLOPEPTIDASE, ENZYME, DRUGGABLE GENOME, PROTEASE | SIMVASTATIN | SIMVASTATIN | 16436088 | |
4313 | MMP2 | NEUTRAL ZINC METALLOPEPTIDASE, ENZYME, DRUGGABLE GENOME, PROTEASE | POLYPHENOL | 15324350 | ||
4313 | MMP2 | NEUTRAL ZINC METALLOPEPTIDASE, ENZYME, DRUGGABLE GENOME, PROTEASE | HEPARAN SULFATE | 12972284 | ||
4313 | MMP2 | NEUTRAL ZINC METALLOPEPTIDASE, ENZYME, DRUGGABLE GENOME, PROTEASE | PRAVASTATIN | PRAVASTATIN | 15842807 | |
4313 | MMP2 | NEUTRAL ZINC METALLOPEPTIDASE, ENZYME, DRUGGABLE GENOME, PROTEASE | RO-26-2853 |
Page: 1 2 3 4 5 6 |